Dalantercept plus axitinib fails to improve progression-free survival in people with kidney cancer

By |2017-06-14T11:30:11+00:0014 Jun 2017|Drug treatments|

The development of dalantercept, an anaplastic lymphoma kinase 1 (ALK1) [...]